Contract Pharma Manufacturing editorial
-
A Future Renaissance At Catalent? Employees Think So
2/8/2024
Re Monday's news of the purchase of Catalent by Novo Holdings, the seminal question we needed a more definitive answer to is: What specifically is planned for Catalent as a CDMO? Chief Editor Louis Garguilo got some answers. “Customers have been calling me continuously,” said one Catalent executive he spoke with.
-
Novo Acquires Catalent, Shakes Up Outsourcing World
2/5/2024
News of Novo Holdings acquiring Catalent, and Novo Nordisk taking in 3 Catalent fill-finish facilities, shakes up the outsourcing industry at a time when so many biopharma sponsors for already starved for capacity. Here's breaking analysis from chief editor Louis Garguilo.
-
Creative Outsourcing Strategies, But Fill-Finish Still A Concern
2/5/2024
Chief Editor Louis Garguilo wraps up his discussions with Thomas Rademacher, CEO, Emergex Vaccines, focusing on strategies that mix internal capacity, facility purchases, CDMOs, new technologies, and challenges with fill-finish outsourcing.
-
Beyond (And Better Than) mRNA: T Cell Vaccines
2/1/2024
During an extraordinary discussion with a historic biotech entrepreneur, he matter-of-factly interjects, “We’re leaving mRNA vaccines in the dust and moving onto a different approach to vaccines.” That ‘dust-generating’ approach is a proprietary T cell-based platform. And it has COVID and many other implications.
-
It's Time To Dethrone CHO When It Comes To mAb Production
2/1/2024
Let’s be honest — CHO is an expensive, inefficient, and pervasive way to make mAbs. Emerging and evolving alternatives discussed here include microbial systems, which tend toward better efficiency.
-
Novel Approaches For Obtaining High-productivity Clones
1/30/2024
Let's dig into cell line selection approaches, transposons to increase copy number for the gene of interest, and targeted integration to rapidly obtain high-productivity clones.
-
Indo-U.S. Collaboration Can Accelerate Drug Discovery — Here’s How
1/30/2024
Innovation in drug discovery can suppress development costs, ultimately improving patient access. Collaborations between India and the U.S. promise to accelerate that innovation on several fronts.
-
Tangential Flow Filtration 101 — The Tech, The Need, And The Market
1/26/2024
Here's a high-level summary of what is increasingly becoming an essential part of the downstream bioprocessing production line.
-
Picking The Best Virus Sample Prep Method In Process Development
1/26/2024
Optimizing downstream operations in viral vaccine development starts with characterization. Learn strategies for picking the best sample prep method.
-
Creating T Cell Vaccines In The Sands
1/25/2024
Like others, Saudi Arabia has been dependent on vaccines supply from abroad. That’s about to change. According to the CEO of Emergex, the Saudis intend to produce a new generation of vaccines – predominantly based on "T cell priming, the next step beyond mRNA vaccines.”